LeadWest Medical Review

What LeadWest Medical charges

• BPC-157: $250/mo — per vial at the entry strength; 10 mg is $325 and 15 mg is $450, and the page closes with "Pricing shown is for presentation and consultation flow purposes"
• Ipamorelin: $170/mo — per vial, sold as a single agent; the CJC-1295/Ipamorelin pairing is $200 at 5 mg/5 mg, and the page closes with "Pricing shown is for presentation and consultation flow purposes"
• CJC-1295: $200/mo — sold only paired with ipamorelin; per vial at the entry strength, with 10 mg/10 mg at $300, under the page note that pricing is "for presentation and consultation flow purposes"
• Epitalon: $200/mo — per vial at the entry strength; 20 mg is $320 and 50 mg is $440, the catalog spells it Epithalon, and pricing is stated to be "for presentation and consultation flow purposes"
• MOTS-C: $220/mo — per vial at the entry strength; 50 mg is $685, under the page note that pricing is "for presentation and consultation flow purposes"
• Sermorelin: $250/mo — per vial at the entry strength; 10 mg is $350 and 15 mg is $450, and the page closes with "Pricing shown is for presentation and consultation flow purposes"
• Tesamorelin: $875/mo — per vial at 30 mg, the only strength captured for it; the page closes with "Pricing shown is for presentation and consultation flow purposes"

A strength beside every figure

The price list does something most of this category avoids: it prints the milligram strength next to each figure, and it prices two or three strengths of the same peptide separately. A shopper can see what a step up in dose actually costs before booking anything.

That structure is why these rows can be rendered at all. The entry strength is recorded as the figure, and the higher strengths are carried in the qualifier beside it, so nothing here is a price floating free of a quantity.

A street address and two working phone numbers in the same area code are published as well, which is more contact detail than most sellers in this comparison offer. No incorporation form appears anywhere on the site, so the entity behind the brand is not established by a document.

The sentence at the bottom of the price list

The list ends with a line saying the pricing shown is for presentation and consultation flow purposes. Read plainly, that withdraws most of what the list appears to promise.

It does not make the figures useless. It makes them indicative, and it means a quote given during a consultation can differ from the page without the seller having contradicted itself. The figures recorded here are the published ones, carrying that sentence with them.

It is worth weighing against the strengths above it. A price list detailed enough to name three strengths per peptide, and then disclaimed at the foot, is a stronger signal about the disclaimer than about the detail.

No extra charges, next to a per-order charge

The peptide page carries a no-extra-charges claim. The pricing page adds a per-order care-logistics and shipping-coordination charge on top of the product price.

Itemizing that charge rather than burying it is the right call, and it is also plainly at odds with the claim on the other page. Both are published today by the same seller.

Neither statement changes what the medication costs. It changes what a shopper should expect an order total to be, which is the number that actually gets paid.

Two states, retatrutide, and a peptide left unmapped

Coverage is California and Nevada. Ten of the twenty-three sellers compared on this site publish a state footprint of any kind, and two states is the narrowest of the ten, so most readers of this comparison cannot buy here at all.

The catalog carries retatrutide, which is not one of the sixteen compounds this site tracks. It has no FDA approval for any indication, which means there is no approved labelling to check a compounded preparation against.

It also sells AOD-9604, Kisspeptin-10, Thymosin Alpha 1, Thymulin, DSIP and 5-Amino-1MQ, none of which is in this site's registry and none of which is scored here.

One product is deliberately left unmapped. The seller lists Thymosin Beta-4 under the parent-protein name, and this site does not record that as TB-500: the registry has no entry for that spelling, and treating one as the other would be a guess rather than a reading.

No compounding pharmacy is named on any peptide page. Six of the twenty-three sellers here name the facility that fills an order.

How we verified this

• Read the peptide price list and recorded the entry-strength figure and the higher strengths published beside it for each compound in this site's registry.
• Recorded the sentence closing the price list verbatim and carried it into the qualifier on every row rather than dropping it.
• Compared the no-extra-charges claim on the peptide page against the per-order charge published on the pricing page.
• Confirmed the service footprint from the seller's own about page wording rather than from a coverage map.
• Recorded the products outside this site's compound registry, including retatrutide, and confirmed no FDA approval exists for it in any indication.
• Left the Thymosin Beta-4 product unmapped after confirming this site's compound registry has no entry for that name.